VC Firms

Portfolio Companies

6

Recent Articles

15

R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment - Fierce Biotech

R1 has emerged from stealth mode after raising $77.5M in a Series A funding round aimed at advancing its treatments for chronic kidney disease.

3/17/2026

Alfred raises $15M Series A - latamlist.com

Alfred has successfully closed a $15M Series A funding round, marking a significant milestone for the company as it looks to expand operations and scale its business across Latin America.

1/26/2026

alfred Raises $15M in Series A Funding - FinSMEs

alfred has successfully raised $15 million in a Series A funding round. The investment is expected to accelerate the company's growth and expand its operations and services.

1/26/2026

F-Prime’s ‘State of Robotics 2025’ report shows record $21 billion investment. But is it another bubble? - Robotics & Automation News

F-Prime's State of Robotics 2025 report reveals a record $21 billion invested in robotics, signaling strong industry growth. However, analysts question whether this surge represents sustainable progress or the makings of another speculative bubble.

11/7/2025

Limitless Raises $10 Million to Expand Decentralized Prediction Markets - Ventureburn

Limitless has secured $10 million in funding to grow its decentralized prediction markets platform, signaling continued investor interest in blockchain-based forecasting tools.

10/21/2025

Arnatar unveils with $52M, dual-modality RNA platform and rare disease asset - Fierce Biotech

Arnatar has launched with $52M in funding, introducing a dual-modality RNA platform targeting rare diseases. The biotech aims to leverage this technology to develop innovative treatments.

8/25/2025

Boom, Bust and Recover: What Happens Next as Biotech VC Cycle Resets - BioSpace

The article examines the biotech venture capital cycle, exploring how the industry moves through boom and bust phases and what recovery may look like as the VC funding landscape resets.

6/4/2025

Here Are The Fintech Companies That Could Go Public In 2025 - Crunchbase News

Crunchbase News highlights fintech companies that may go public in 2025, identifying key players poised for IPOs as market conditions potentially improve for tech listings.

6/3/2025

Sprinter Health nabs $55M — Fierce Fundraising Tracker - Fierce Healthcare

Sprinter Health secured $55 million in funding, as tracked by Fierce Healthcare's fundraising monitor covering notable investment activity in the healthcare sector.

6/2/2025

Stephen Knight: Investing in Biotech Solutions - Yale Insights

Stephen Knight discusses his approach to investing in biotechnology, focusing on identifying innovative solutions and evaluating the potential of science-driven companies to address critical healthcare challenges.

10/31/2024

Wilson Sonsini Advises Novo Holdings and F-Prime Capital on AvenCell’s $112 Million Series B - Wilson Sonsini

Wilson Sonsini advised Novo Holdings and F-Prime Capital on AvenCell's $112 million Series B financing round, supporting the biotech company's growth and development efforts.

10/22/2024

The march toward viable AI use cases - The Financial Revolutionist

The article explores the progress of AI adoption in financial services, highlighting the shift from experimentation to practical, viable use cases driving real business value.

7/9/2024

F-Prime Capital Releases its 2024 State of Fintech Report - PR Newswire

F-Prime Capital has released its 2024 State of Fintech Report, offering insights into the current landscape and trends shaping the financial technology sector.

2/6/2024

F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn - biopharmadive.com

F-Prime Capital's Ketan Patel discusses the bias against experienced founders in biotech, dubbed 'reverse ageism,' and shares his perspective on smart investing strategies during a market downturn.

6/30/2023

How the owners of Fidelity get richer at everyday investors’ expense - Reuters

Reuters investigates how Fidelity's private owners benefit financially in ways that may come at the cost of ordinary investors who use the firm's investment products and services.

10/5/2016

Related VC Firms